@article{MRA, author = {Ericka Barrientos-Zavalza and Celia Piña-Leyva and Manuel Lara-Lozano and Gonzalo Flores and Daniel Martínez-Fong and Bertha León-Chávez and Anabel Jiménez-Anguiano and Juan Gonzalez-Barrios}, title = { Cerebrolysin Improves Motor Abilities and Reverses the Long-Term Memory Acquisition Deficit in Rats with Hypoxic-Ischemic Encephalopathy}, journal = {Medical Research Archives}, volume = {11}, number = {8}, year = {2023}, keywords = {}, abstract = {Background: Hypoxic-ischemic encephalopathy (HIE) is a neurological condition that leads to motor disabilities and even death in neonates. Unfortunately, few therapeutic alternatives can contribute to brain recovery after HIE damage. Cerebrolysin is a neuropeptide mixture that exerts neuroprotective and neurotrophic effects on injured brain tissue after systemic administration. Aims: This study evaluated the short- and long-term beneficial effects of Cerebrolysin administration in a rat model of HIE. Methods: Neonatal 7-day-old rats were subjected to hypoxia-ischemia injury and then intraperitoneally administered Cerebrolysin (10 mL/kg of body weight) once a day for 7 days, from postnatal days 8 to 14. Growth development, blood-brain barrier permeability, and neurobehavioral tests were performed. Results: Cerebrolysin administration after hypoxic-ischemic insult minimized brain damage, edema and increased cellular viability. Furthermore, this neuroprotective effect improves some motor abnormalities and, during adulthood, reverses the long-term memory acquisition deficit caused by HIE. Conclusion: Repeated Cerebrolysin administration can safely and effectively reduce HIE motor disabilities and reverse long-term memory acquisition deficits in neonatal rats.}, issn = {2375-1924}, doi = {10.18103/mra.v11i8.4345}, url = {https://esmed.org/MRA/mra/article/view/4345} }